Diagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: The HGM-3 index

HIV Medicine

Volumn 11, Issue 1, 2010, Pages 64-73

  Resino, S ^a   Micheloud, D ^a   Miralles, P ^b   Bellon J M ^c   Vargas, A ^a   Catalan P ^d   Alvarez E ^e   Cosin J ^b   Lorente, R ^f   Lopez J C ^b   Munoz Fernandez M A ^f   Berenguer, J ^b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Infectious Diseases Unit   (Spain)

^c Biomedical Research Foundation   (Spain)

^d Depto de Microbiol Medica   (Spain)

^e Pathology Department   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Chronic hepatitis C; Diagnostic accuracy; Liver cirrhosis; Liver fibrosis; Serum predictive markers

Indexed keywords

ALKALINE PHOSPHATASE; HYALURONIC ACID; INTERFERON; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; HEPATITIS C; HGM 3 INDEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MIXED INFECTION; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; THROMBOCYTE COUNT;

ADULT; ALKALINE PHOSPHATASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HEPATOCYTE GROWTH FACTOR; HIV INFECTIONS; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; MALE; PLATELET COUNT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 72449176869     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00745.x     Document Type: Article

References (41)

1. Soto B, Sanchez-Quijano A, Rodrigo L. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997, 26:1-5.
2. Benhamou Y, Bochet M, Di Martino V. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999, 30:1054-1058.
3. Bica I, McGovern B, Dhar R. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492-497.
4. Graham CS, Baden LR, Yu E. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562-569.
5. Garcia-Samaniego J, Rodriguez M, Berenguer J. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001, 96:179-183.
6. Yano M, Kumada H, Kage M. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996, 23:1334-1340.
7. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006, 20:49-57.
8. Giron-Gonzalez JA, Brun F, Terron A, Vergara A, Arizcorreta A. Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study. Antivir Ther 2007, 12:899-907.
9. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008, 134:1670-1681.
10. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000, 32:477-481.
11. Regev A, Berho M, Jeffers LJ. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
12. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
13. Saito H, Tada S, Nakamoto N. Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatol Res 2004, 29:97-103.
14. Castera L, Vergniol J, Foucher J. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
15. Forns X, Ampurdanes S, Sanchez-Tapias JM. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001, 35:265-271.
16. Wai CT, Greenson JK, Fontana RJ. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
17. Sterling RK, Lissen E, Clumeck N. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
19. Jacobs WH, Goldberg SB. Statement on outpatient percutaneous liver biopsy. Dig Dis Sci 1989, 34:322-323.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
21. Berenguer J, Bellon JM, Miralles P. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007, 14:859-869.
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
23. Song HH. Analysis of correlated ROC areas in diagnostic testing. Biometrics 1997, 53:370-382.
24. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003, 56:1129-1135.
25. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005, 115:209-218.
26. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007, 117:524-529.
27. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006, 44:462-474.
28. Halfon P, Bacq Y, De Muret A. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007, 46:395-402.
29. Larrousse M, Laguno M, Segarra M. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007, 46:304-311.
30. Kelleher TB, Mehta SH, Bhaskar R. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA Index. J Hepatol 2005, 43:78-84.
31. Asano Y, Iimuro Y, Son G, Hirano T, Fujimoto J. Hepatocyte growth factor promotes remodeling of murine liver fibrosis, accelerating recruitment of bone marrow-derived cells into the liver. Hepatol Res 2007, 37:1080-1094.
32. Lichtinghagen R, Bahr MJ. Noninvasive diagnosis of fibrosis in chronic liver disease. Expert Rev Mol Diagn 2004, 4:715-726.
33. Thuluvath PJ, Krok KL. Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Am J Gastroenterol 2005, 100:1981-1983.
34. Zeremski M, Talal AH. Noninvasive markers of hepatic fibrosis: are they ready for prime time in the management of HIV/HCV co-infected patients? J Hepatol 2005, 43:2-5.
35. Poynard T, Munteanu M, Imbert-Bismut F. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004, 50:1344-1355.
36. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004, 99:1160-1174.
37. de Ledinghen V, Douvin C, Kettaneh A. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006, 41:175-179.
38. Nunes D, Fleming C, Offner G. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005, 40:538-544.
39. Cacoub P, Carrat F, Bedossa P. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study-ANRS HC02. J Hepatol 2008, 48:765-773.
40. Loko MA, Castera L, Dabis F. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine Cohort. Am J Gastroenterol 2008, 103:1973-1980.
41. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006, 55:409-414.